Wednesday, July 8, 2026

pharma · Hypercholesterolemia · Hyperlipidemia · ESPR

Esperion Therapeutics

Esperion Therapeutics clinical programs — 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
Status
Public
HQ
Ann Arbor, US
Employees
5
Programs
15
Drugs
9
Patents
55
Intelligence · Clinical Programs

Esperion Therapeutics projects

15 ClinicalTrials.gov programs sponsored by Esperion Therapeutics.

Esperion Therapeutics has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Bempedoic Acid + Ezetimibe Fixed-Dose Combination

    Esperion Therapeutics

    Hyperlipidemias

    phase 3 other completed

    1 trial
  2. Bempedoic acid 180 mg tablet

    Esperion Therapeutics

    Cardiovascular Diseases

    phase 3 small molecule completed

    1 trial
  3. ETC-1002

    Esperion Therapeutics

    Hypercholesterolemia

    phase 3 small molecule completed

    6 trials
  4. bempedoic acid

    Esperion Therapeutics

    Hypercholesterolemia

    phase 3 small molecule completed

    5 trials
  5. Bempedoic acid + Ezetimibe FDC Oral Tablet

    Esperion Therapeutics

    Diabetes

    phase 2 small molecule completed

    1 trial
  6. Bempedoic acid 180mg

    Esperion Therapeutics

    Hypercholesterolemia

    phase 2 small molecule completed

    2 trials
  7. Bempedoic acid, bempedoic acid

    Esperion Therapeutics

    Heterozygous familial hypercholesterolemia, Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule active

    1 trial
  8. ETC-1002

    Esperion Therapeutics

    Dyslipidemia

    phase 2 small molecule completed

    1 trial
  9. ETC-1002

    Esperion Therapeutics

    Hyperlipidemia

    phase 2 small molecule completed

    2 trials
  10. ETC-1002

    Esperion Therapeutics

    Safety Evaluation of Escalating Doses

    phase 1 small molecule completed

    1 trial
  11. ETC-1002 or placebo

    Esperion Therapeutics

    Mild Dyslipidemia

    phase 1 small molecule completed

    1 trial
  12. [14C-ETC-1002]

    Esperion Therapeutics

    Hyperlipidemia

    phase 1 small molecule completed

    1 trial
  13. Bempedoic Acid / Ezetimibe Oral Tablet

    Esperion Therapeutics

    Cardiovascular Diseases

    approved small molecule active

    1 trial
  14. Bempedoic Acid 180 MG Oral Tablet

    Esperion Therapeutics

    Healthy Lactating Women

    approved small molecule completed

    1 trial
  15. Cardiopulmonary Exercise Testing

    Esperion Therapeutics

    Intrauterine Growth Restriction

    other active

    1 trial

Frequently asked questions

How many clinical projects does Esperion Therapeutics have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.